Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024623 (gastric cancer)
 36,219 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In the present study, an antigastric cancer monoclonal antibody, MGb2, was chosen to prepare an antibody-daunomycin conjugate. Daunomycin was modified by cis-aconitic anhydride, and the derivative was linked to antibody, a carbodiimide reagent being used to produce peptide bonding. Four to five molecules of daunomycin were specifically bound per molecule of antibody, without severely impairing the pharmacological activity of daunomycin and with minimal loss of antibody activity. A tetrazolium dye colorimetric assay indicated that the MGb2-daunomycin conjugate exhibited selective cytotoxicity against human gastric cancer cells SGC-7901 in vitro. The tumor localization in BALB/c nude mice showed that the specific conjugate could recognize the tumor as efficiently as the unconjugated antibody. MGb2-daunomycin conjugate could significantly suppress the growth of human gastric carcinoma GAII inoculated under the renal capsules of BALB/c nude mice. Intraperitoneal injection of MGb2-daunomycin conjugate twice a week for 3 weeks at a dose of 1 mg/kg of drug gave a tumor inhibition rate of 91.58%, far more effective than free daunomycin or an irrelevant conjugate.
 ...
PMID:Enhanced antitumor activity of daunomycin conjugated with antigastric cancer monoclonal antibody MGb2. 129 75

The cytotoxicities of 2 derivatives of artemisinin B and 2 derivatives of artemisic acid (designated as Compound A, B, C, and D) were investigated, using trypan blue dye exclusion test and colony-forming units assay. At the concentration of 5 micrograms.ml-1, the inhibition rates of these 4 compounds against murine leukemia cell line P388 were > 85%. When tested against human hepatoma cell line SMMC-7721 at 25 micrograms.ml-1, the inhibition rates of Compound A, B, C, and D were found to be 92.3%, 96.9%, 84%, and 82.1%, respectively, and 27%, 8%, 37.8%, 1.7% against normal human embryonic lung cell line WI-38, respectively. These 4 compounds all showed an inhibition rate of 100% against human gastric cancer cell line SGC-7901 at 50 micrograms.ml-1.
 ...
PMID:[Antitumor activities of 4 derivatives of artemisic acid and artemisinin B in vitro]. 130 44

Biotinylated ricin A chain (RTA) was introduced to antigastric cancer monoclonal antibody MGb2 with chemical conjugating technique to form an immuno-ricin A chain conjugate (I-RTA) specific for gastric cancer. Its internalization in human gastric cancer cell line SGC-7901 was followed by double dynamic EM labelling procedure using streptavidin-gold and sheep anti-mouse IgG-gold probes. The effects of verapamil on I-RTA internalization routings were also observed. The results demonstrated that the main entry modality of I-RTA was non-coated microinvagination, followed by coated pits and interioration of microvilli. The internalized I-RTA was found to be quickly transported to multivesicular bodies and finally to lysosomes, where it was degraded, whilst in the non-membranous structures I-RTA was only occasionally encountered. Ultrastructurally, verapamil displayed its effects by making the internalized I-RTA stay longer in tubulovesicular structures and be delivered in a less amount and more slowly into lysosomes. Furthermore, I-RTA was increased in the non-membranous structures, and the in vitro killing effect was significantly enhanced. The present data revealed the basic cell biology process of I-RTA-cell interaction, which will provide not only an important clue to improving I-RTA targeting therapy efficiency, but also a new way for further screening targeting potentiators.
 ...
PMID:[Immuno-ricin A chain specific for gastric cancer: internalization and its significance]. 133 Feb 28

Boron neutron capture therapy (BNCT) is based on the nuclear reaction yielding high LET Li-7 and alpha particles when boron-10 is irradiated with thermal neutrons. (Et4N)2(10)B10H10 was entrapped in 40 nm liposomes coating the monoclonal antibody, MGb 2, against human gastric cancer. There were 1.4 x 10(4) 10B atoms encapsulated and 20 molecules of MGb 2 incorporated per liposomes ELISA indicated that the immunoreactivity of antibodies on liposomes retained 80%. Preferred binding to human gastric cancer cell line SGC-7901 was observed as many as 15.1 x 10(9) 10B atoms/tumor cell, 38-fold more than that to normal human embryonic lung cell line SL 7. The fluorescent immunoliposome-stained tumor cells showed membrane-fluorescence while SL 7 cells showed no obvious fluorescence. Irradiated with thermal neutrons (0.025 eV, 3.12 x 10(11)n/cm2, gamma-ray 0.84 Gy), 10B-containing immunoliposomes pretreated SGC-7901 cells survived 27%, significantly lower than non-irradiated cells or non-pretreated cells with irradiation (P less than 0.001). The results demonstrated that boron-containing immunoliposomes could bind selectively and deliver sufficient amount of boron-10 to the target tumor cells.
 ...
PMID:[Boron neutron capture therapy of human gastric cancer by boron-containing immunoliposomes under thermal neutron irradiation]. 166 91

In the present study, an anti-gastric cancer monoclonal antibody, MGb2, was chosen to prepare antibody-mitomycin C (MMC) conjugate with dextran T-40 as intermediary. Twenty molecules of MMC were introduced into each molecule of antibody while the antigen-binding capacity of the antibody was kept well. The conjugate showed selective cytotoxicity upon human gastric cancer cell line SGC-7901. Radioimmunoimaging and biodistribution studies indicated that after conjugation with MMC via dextran T-40 as intermediary, the tumor localization capacity of the antibody was well retained. When tested in nude mice, inoculated with human gastric carcinoma SGC-7901 in bilateral subrenal capsules, intraperitoneal injection of the conjugate daily for 6 days at a dose of 1 mg/kg gave a tumor inhibitory rate of 68.67%, which was far better than that of free MMC or irrelevant conjugate. No synergetic effect was found in regard to the mixture of MGb2 with MMC.
 ...
PMID:Specific targeting of mitomycin C to tumors by anti-gastric cancer monoclonal antibody. 190 61

In the present study, an antigastric cancer monoclonal antibody, MGb2, was chosen to prepare antibody-mitomycin C conjugate with dextran T-40 as intermediary. Up to 20 molecules of mitomycin C were specifically bound per molecule of antibody, without significantly impairing the antigen-binding capacity of the antibody and the pharmacological activity of mitomycin C. The conjugate showed selective cytotoxicity upon human gastric cancer cell line SGC-7901 in vitro. Radioimmunoimaging and biodistribution studies indicated that, after conjugation with mitomycin C via dextran T-40 as intermediary, the tumor localization capacity of the antibody was well-retained. When tested in nude mice inoculated with human gastric carcinoma GAII in bilateral subrenal capsules, intraperitoneal injection of the conjugate twice a week for 3 weeks at the dose of 1 mg/kg of drug gave a tumor inhibitory rate of 152.29%, the result being far better than that of free mitomycin C or an irrelevant conjugate. A similar result was found in another nude mouse model of human gastric carcinoma SGC-7901. Meanwhile, after conjugation with antibody, the toxicity of mitomycin C on tested animals was significantly reduced.
 ...
PMID:Preparation of antigastric cancer monoclonal antibody MGb2-mitomycin C conjugate with improved antitumor activity. 212 14

A conjugate of an anti-gastric cancer monoclonal antibody and mitomycin C linked by polyaldehyde dextran T-40 (MGb2-PAD-MMC) was prepared. Nude mice inoculated with human gastric cancer (SGC-7901) xenograft in bilateral subrenal capsule were treated ip with the conjugate at a daily dose containing MGb2 22.4 mg/kg and MMC 1 mg/kg for 6 d since 4 h after inoculation. The efficacy of the conjugate was estimated by the reduction of tumor size which calculated by T/C (%) was 32.2%. If MGb2 in the conjugate was replaced by a normal nude mice IgG (NIgG-PAD-MMC) or the nude mice were treated ip with the dose of MMC alone, the tumor T/C (%) were 58 and 87%, respectively. It was statistically significant between MGb2-PAD-MMC and NIgG-PAD-MMC or MMC treatment. When the above mentioned nude mice with SGC-7901 were treated ip with thrice dose of the conjugate (MGb2 67.2 mg/kg and MMC 3 mg/kg) for 6 d, the tumor growth was inhibited completely. Nevertheless, the same dose of MMC was given to the nude mice resulted in toxic appearance included anorexia, weight loss or even death. Furthermore, when the nude mice were treated ip with MGb2-PAD-MMC 24 h after inoculation, no apparent therapeutic effect was seen. In some experiments, nude mice inoculated with another human transplanted gastric tumor (GA II) xenograft treated ip with a conjugate of MGb2 and MMC or daunorubcin (Dau) 1 day after inoculation.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Effects of immuno-drug conjugates on growth of human gastric cancer xenograft in subrenal capsule of nude mice]. 213 Jun 22

In the present study, an anti-gastric cancer monoclonal antibody, MGb2, was chosen to prepare antibody-mitomycin C (MMC) conjugate with dextran T-40 as intermediary. 20 molecules of MMC were introduced into each molecule of antibody, while the antigen-binding capacity of the antibody was kept well. The conjugate showed highly selective cytotoxicity upon human gastric cancer cell line SGC-7901. Radioimmunoimaging and biodistribution studies indicated that after conjugation with MMC via dextran T-40 as intermediary, the tumor localization capacity of the antibody was well retained. When tested in nude mice, by inoculation with human gastric carcinoma SGC-7901 in bilateral subrenal capsules, intraperitoneal injection of the conjugate daily for 6 days at the dose of 1 mg/kg of drug gave a tumor inhibitory rate of 68.67%, the result being far better than that of free MMC or irrelevant conjugate. No synergic effect was found in regard to the mixture of MGb2 with MMC.
 ...
PMID:[Specific targeting of mitomycin C to tumors with the use of anti-gastric cancer monoclonal antibody]. 217 25

After the human gastric cancer cells SGC-7901 were cultured with 5 mM hexamethylene bisacetamide (HMBA) for 120 hr, cell growth was inhibited. The doubling time increased from 48 hr in untreated cells to 99.6 hr in HMBA-treated cells. The maximal increase in growth was 2.4-fold as compared to 6.4-fold in the untreated control. 3H-thymidine incorporation was inhibited by HMBA and the colony formation rate was reduced. There was concomitant decrease in carcino-embryonic antigen and beta-2 microglobulin as determined by radioimmuno-assay. Lactic dehydrogenase (LDH) and its isoenzyme assay revealed a marked increase in H-type LDH but the total enzyme activity was reduced. These results indicate that HMBA inhibits proliferation of SGC-7901 cells in vitro.
 ...
PMID:[Effect of hexamethylene bisacetamide on human gastric cancer cell line SGC-7901]. 219 72

We have studied and found antitumor effects in Chinese green tea extracts (T-8750). By pharmacologic test, it showed anticancer actions against several kinds of tumors in NIH mice evidently. Clinical trials on the therapeutics effects against early stomach cancer showed very effective. In order to prove it's function to prevent cancer. The research results as follows: (1) In vitro, T-8750 (0.5-1 mg/ml) could inhibit the cell growth of SGC (stomach gastric cancer) significantly. The inhibition action are obviously within 12-24 hr. (2) T-8750 traversed the migration of cell line L1210 from G1 phase to S phase, the rate were (63%). (3) In vitro, the blocking effect of T-8750 on the nitrosation of morpholine-nitrite was (92.4%). (4) the effect of T-8750 scavenger harmful free radicals was (63%).
 ...
PMID:[Effect of Chinese green tea extracts on the human gastric carcinoma cell in vitro]. 236 2


1 2 3 4 5 6 7 8 9 10 Next >>